ViroGates A/S (VIRO) - Net Assets
Based on the latest financial reports, ViroGates A/S (VIRO) has net assets worth Dkr16.79 Million DKK (≈ $2.63 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Dkr26.77 Million ≈ $4.19 Million USD) and total liabilities (Dkr9.98 Million ≈ $1.56 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check ViroGates A/S PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Dkr16.79 Million |
| % of Total Assets | 62.72% |
| Annual Growth Rate | 3.04% |
| 5-Year Change | 18.12% |
| 10-Year Change | 115.95% |
| Growth Volatility | 587.34 |
ViroGates A/S - Net Assets Trend (2015–2025)
This chart illustrates how ViroGates A/S's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see ViroGates A/S market cap and net worth.
Annual Net Assets for ViroGates A/S (2015–2025)
The table below shows the annual net assets of ViroGates A/S from 2015 to 2025. Also explore VIRO net assets growth trend to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Dkr19.40 Million ≈ $3.04 Million |
+79.74% |
| 2024-12-31 | Dkr10.79 Million ≈ $1.69 Million |
-36.53% |
| 2023-12-31 | Dkr17.01 Million ≈ $2.66 Million |
+5.71% |
| 2022-12-31 | Dkr16.09 Million ≈ $2.52 Million |
-2.06% |
| 2021-12-31 | Dkr16.43 Million ≈ $2.57 Million |
-47.54% |
| 2020-12-31 | Dkr31.31 Million ≈ $4.90 Million |
-25.82% |
| 2019-12-31 | Dkr42.22 Million ≈ $6.60 Million |
-30.81% |
| 2018-12-31 | Dkr61.01 Million ≈ $9.55 Million |
+1935.74% |
| 2017-12-31 | Dkr3.00 Million ≈ $468.90K |
-66.64% |
| 2016-12-31 | Dkr8.98 Million ≈ $1.41 Million |
-37.55% |
| 2015-12-31 | Dkr14.39 Million ≈ $2.25 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to ViroGates A/S's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 16.9% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Dkr10.12 Million | 52.15% |
| Common Stock | Dkr9.28 Million | 47.85% |
| Total Equity | Dkr19.40 Million | 100.00% |
ViroGates A/S Competitors by Market Cap
The table below lists competitors of ViroGates A/S ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
T3 Defense Inc.
NYSE:DFNS
|
$14.68 Million |
|
SDN Company. Ltd
KQ:099220
|
$14.69 Million |
|
Ambitions Enterprise Management Co. L.L.C Class A Ordinary Shares
NASDAQ:AHMA
|
$14.69 Million |
|
DELPHI WORLD MONEY LIMITED
NSE:DELPHIFX
|
$14.69 Million |
|
Aurora Labs Ltd
AU:A3D
|
$14.65 Million |
|
Air Industries Group
NYSE MKT:AIRI
|
$14.65 Million |
|
Vakif Menkul Kiymet Yatirim Ortakligi AS
IS:VKFYO
|
$14.65 Million |
|
Glennon Small Companies Ltd
AU:GC1
|
$14.64 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ViroGates A/S's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 10,795,000 to 19,403,000, a change of 8,608,000 (79.7%).
- Net loss of 10,397,000 reduced equity.
- New share issuances of 19,005,000 increased equity.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Dkr-10.40 Million | -53.58% |
| Share Issuances | Dkr19.00 Million | +97.95% |
| Total Change | Dkr- | 79.74% |
Book Value vs Market Value Analysis
This analysis compares ViroGates A/S's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.11x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 2.01x to 4.11x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | Dkr5.01 | Dkr10.10 | x |
| 2016-12-31 | Dkr3.13 | Dkr10.10 | x |
| 2017-12-31 | Dkr1.23 | Dkr10.10 | x |
| 2018-12-31 | Dkr20.59 | Dkr10.10 | x |
| 2019-12-31 | Dkr10.74 | Dkr10.10 | x |
| 2020-12-31 | Dkr7.83 | Dkr10.10 | x |
| 2021-12-31 | Dkr4.02 | Dkr10.10 | x |
| 2022-12-31 | Dkr3.81 | Dkr10.10 | x |
| 2023-12-31 | Dkr4.91 | Dkr10.10 | x |
| 2024-12-31 | Dkr1.62 | Dkr10.10 | x |
| 2025-12-31 | Dkr2.46 | Dkr10.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ViroGates A/S utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -53.58%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -195.91%
- • Asset Turnover: 0.17x
- • Equity Multiplier: 1.58x
- Recent ROE (-53.58%) is above the historical average (-76.86%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -28.29% | -113.28% | 0.21x | 1.21x | Dkr-5.51 Million |
| 2016 | -60.13% | -146.58% | 0.31x | 1.34x | Dkr-6.30 Million |
| 2017 | -199.77% | -245.27% | 0.49x | 1.66x | Dkr-6.29 Million |
| 2018 | -27.84% | -512.24% | 0.05x | 1.04x | Dkr-23.09 Million |
| 2019 | -44.53% | -524.76% | 0.08x | 1.07x | Dkr-23.02 Million |
| 2020 | -59.83% | -349.94% | 0.14x | 1.22x | Dkr-21.87 Million |
| 2021 | -107.53% | -230.71% | 0.38x | 1.23x | Dkr-19.31 Million |
| 2022 | -59.96% | -63.47% | 0.87x | 1.09x | Dkr-11.25 Million |
| 2023 | -71.12% | -173.12% | 0.28x | 1.44x | Dkr-13.80 Million |
| 2024 | -132.89% | -292.93% | 0.28x | 1.64x | Dkr-15.42 Million |
| 2025 | -53.58% | -195.91% | 0.17x | 1.58x | Dkr-12.34 Million |
Industry Comparison
This section compares ViroGates A/S's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $3,216,379,600
- Average return on equity (ROE) among peers: 10.34%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ViroGates A/S (VIRO) | Dkr16.79 Million | -28.29% | 0.59x | $14.67 Million |
| Ambu A/S (AMBU-B) | $854.00 Million | 17.68% | 1.40x | $2.35 Billion |
| ChemoMetec A/S (CHEMM) | $43.23 Million | 0.80% | 0.18x | $1.34 Billion |
| Demant A/S (DEMANT) | $9.34 Billion | 19.22% | 2.27x | $9.76 Billion |
| GN Store Nord (GN) | $5.76 Billion | 13.97% | 0.94x | $2.16 Billion |
| Scandinavian Medical Solutions AS (SMSMED) | $82.67 Million | 0.03% | 1.49x | $11.48 Million |
About ViroGates A/S
ViroGates A/S, an in vitro diagnostics company, develops and sells blood tests for measuring chronic inflammation for the healthcare sector. It offers suPARnostic TurbiLatex, a CE-IVD approved particle-enhanced turbidimetric immunoassay for quantitative measurement of suPAR in human plasma; suPARnostic AUTO Flex ELISA kit, a fully quantitative immunoassay designed for accurate and reliable measur… Read more